Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Return on Equity (2018 - 2019)

Historic Return on Equity for Monopar Therapeutics (MNPR) over the last 3 years, with Q3 2020 value amounting to 0.08%.

  • Monopar Therapeutics' Return on Equity rose 7400.0% to 0.08% in Q3 2020 from the same period last year, while for Sep 2020 it was 0.08%, marking a year-over-year increase of 7400.0%. This contributed to the annual value of 0.44% for FY2019, which is 400.0% down from last year.
  • As of Q3 2020, Monopar Therapeutics' Return on Equity stood at 0.08%, which was up 7400.0% from 0.16% recorded in Q2 2020.
  • Monopar Therapeutics' Return on Equity's 5-year high stood at 0.08% during Q3 2020, with a 5-year trough of 2.03% in Q2 2018.
  • Moreover, its 3-year median value for Return on Equity was 0.5% (2019), whereas its average is 0.71%.
  • The largest annual percentage gain for Monopar Therapeutics' Return on Equity in the last 5 years was 13000bps (2019), contrasted with its biggest fall of -4500bps (2019).
  • Quarter analysis of 3 years shows Monopar Therapeutics' Return on Equity stood at 0.44% in 2018, then dropped by -15bps to 0.5% in 2019, then soared by 84bps to 0.08% in 2020.
  • Its last three reported values are 0.08% in Q3 2020, 0.16% for Q2 2020, and 0.23% during Q1 2020.